News

Oral Azacitidine After Achieving Remission in AML Improves Survival and Does Not Worsen Quality of Life

10. 10. 2023 Source: Acute Myeloid Leukemia

Orally administered azacitidine as maintenance therapy in patients with acute myeloid leukemia (AML) after achieving remission provides a favorable effect in terms of fatigue and improving health-related quality of life (HRQoL). This is based on the results of the QUAZAR AML-001 study, which were published in the journal Haematologica.

Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children

Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with…

10. 10. 2023 Source: Rare Diseases in Neurology

Myasthenia Gravis and Unmet Patient Needs –⁠ Data from Clinical Practice

Myasthenia gravis (MG) is a rare, chronic, disabling, unpredictable, and potentially life-threatening autoimmune neuromuscular disease. There is still a lack of sufficient data from real clinical…

10. 10. 2023 Source: Rare Diseases in Neurology

Definition and Classification of Chronic Kidney Disease According to KDIGO

We provide a brief overview of the definition and classification of chronic kidney disease based on the updated KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines from 2012...

9. 10. 2023 Source: Cardiovascular Risks

Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia

Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with…

9. 10. 2023 Source: Modern Treatment of Schizophrenia

Physical Activity in Young Men with Hemophilia A

What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.

6. 10. 2023 Source: Hemophilia with Movement

N9-GP in Previously Treated Pediatric Patients with Hemophilia B –⁠ Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.

4. 10. 2023 Source: Hemophilia with Movement

artroplastika kyčelního a kolenního kloubu

Pain Management in Patients After Hip and Knee Arthroplasty –⁠ Data from Clinical Practice

Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of…

3. 10. 2023 Source: Analgesia

Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency –⁠ Real-World Data

Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy...

2. 10. 2023 Source: Primary and Secondary Immunodeficiencies

Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment –⁠ Case Study

In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize…

2. 10. 2023 Source: Immune Thrombocytopenia

Romiplostim in ITP Treatment –⁠ Data from German Clinical Practice

Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and…

2. 10. 2023 Source: Immune Thrombocytopenia

Invasive Pneumococcal Disease –⁠ Current Czech Data

The number of reported cases of invasive pneumococcal disease (IPD) returned to levels comparable to those before the COVID-19 pandemic in 2022. Regarding age-specific morbidity, the most at-risk…

2. 10. 2023 Source: Regular Vaccination

Do Gliflozins Affect the Need to Use Diuretics?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to…

1. 10. 2023 Source: Heart Failure

INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives –⁠ current trend

The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study.…

28. 9. 2023 Source: Treatment of Glaucoma

Rapid Strengthening and Long-term Stabilization –⁠ New Strategy for Sequential Treatment of Severe Osteoporosis

Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting…

27. 9. 2023 Source: Osteoporosis – Trends in Sequential Therapy

1 … 21 22 23 24 25 … 115

Back Filter by speciality

Remove filters